BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Xue Y, Zhang LX, Wang L, Li T, Qu YD, Liu F. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. World J Gastroenterol 2017; 23(32): 5969-5976 [PMID: 28932089 DOI: 10.3748/wjg.v23.i32.5969]
URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5969.htm
Number Citing Articles
1
Yuvaram N. V. Reddy, David Nunes, Vipul Chitalia, Craig E. Gordon, Jean M. Francis. Hepatitis C virus infection in kidney transplantation‐changing paradigms with novel agentsHemodialysis International 2018; 22(S1) doi: 10.1111/hdi.12659
2
Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with SofosbuvirCanadian Journal of Gastroenterology and Hepatology 2020; 2020: 1 doi: 10.1155/2020/1632959
3
Hossam Gewaid, Ahmed A. Mesalam, Ahmed A. Ibrahim, Dina N. Abdel Shafy, Rola N. Abdel Shafy, Nahed Emara, Soha M. Hamdy, Mohy Gewaid, Mahmoud M. Bahgat. Establishment of a platform for molecular and immunological characterization of the RNA‐dependent‐RNA‐polymerase NS5B of an Egyptian HCV isolateJournal of Medical Virology 2018; 90(3): 545 doi: 10.1002/jmv.24977
4
Radwa Samir Hagag, Morkoss Medhat Fakhry, Ossama Ashraf Ahmed, Shaimaa Abdalaleem Abdalgeleel, Mahasen Aly Radwan, Gina Gamal Naguib. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational studyThe Egyptian Journal of Internal Medicine 2022; 34(1) doi: 10.1186/s43162-022-00126-8
5
Cahyani Gita Ambarsari, Eka Laksmi Hidayati, Irsan Hasan, Angela Grace, Hanifah Oswari. <p>Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series</p>International Journal of Nephrology and Renovascular Disease 2020; : 139 doi: 10.2147/IJNRD.S248632
6
HanyMohammed Ibrahim, FatenRoshdy Abdel-Ghaffar, AhmedBahgat Zied, SamehaHusni El-Ghareeb. Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcomeBiomedical and Biotechnology Research Journal (BBRJ) 2022; 6(1): 109 doi: 10.4103/bbrj.bbrj_209_21
7
Matthew Kadatz, Scott Klarenbach, Jagbir Gill, John S. Gill. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test–positive donors for transplantation in hepatitis C–negative recipientsAmerican Journal of Transplantation 2018; 18(10): 2457 doi: 10.1111/ajt.14929
8
Sreekumar Othumpangat, John D. Noti. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2018; 40: 345 doi: 10.1016/bs.seda.2018.08.005
9
Aamir Bashir, Ashish Verma, Ajay Duseja, Arka De, Pramil Tiwari. Adjuvant use of ribavirin with treatment of hepatitis C virus in kidney transplant recipients: A systematic review and meta-analysis of real-world dataIndian Journal of Transplantation 2022; 16(3): 243 doi: 10.4103/ijot.ijot_10_22
10
Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar AC, Sanjay Hadigal. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regionsWorld Journal of Gastroenterology 2019; 25(29): 3897-3919 doi: 10.3748/wjg.v25.i29.3897